Skip to content

Prospective Validation of AKI Prediction

Prospective Validation of AKI Prediction Algorithm

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06804200
Enrollment
800
Registered
2025-02-03
Start date
2025-06-25
Completion date
2027-08-01
Last updated
2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Machine Learning, Pediatrics, Critical Care

Brief summary

The purpose of this prospective observational study is to implement, deploy, and quantify accuracy of an existing Pediatric Early AKI Risk Score algorithm. The implementation will be facilitated using a Health Level 7 (HL7) Fast Healthcare Interoperability Resource (FHIR)-based architecture. Investigators will deploy this model and store results in a manner not viewable to the clinical team caring for the patient. To determine the accuracy of the implemented prediction model, Investigators will prospectively identify patients with AKI at 72 hours following ICU admission. Investigators hypothesize that this model will prospectively detect AKI with a sensitivity \>70% and a positive predictive value \>20%, both chosen a priori as 10% improvement over the initial Pediatric AKI Risk Score tool.

Detailed description

This is a single-center prospective observational study validating an AKI predictive model. Each model feature will be mapped to an appropriate FHIR-based resource. To mitigate the latency issues seen in other distributed CDS systems, Investigators have developed an asynchronous design where algorithm calculations are performed offline (e.g., not within the EHR) and risk scores are subsequently written back to the EHR. Importantly, in this deployment, model output and resulting clinical risk score will not be communicated to the treating clinicians. During the study period, Investigators will review charts daily for all patients admitted to the Golisano Children's Hospital PICU, a 12-bed facility adjacent to our 15-bed Pediatric Cardiac Intensive Care Unit (PCICU). Using a standard protocol to screen and identify patients by chart review, Investigators will generate a list of patients who meet AKI KDIGO criteria by SCr and urine output, along with recorded clinical information about these patients. At the conclusion of the study period, this list will be used as the "gold standard" and compared to the automated screening tool to determine the tool's test characteristics. Model assessment outcomes include sensitivity, positive predictive value (PPV), and number needed to alert (NNA) to prospectively identify AKI in a population of critically ill children. Additional outcomes include timeliness of identification based on model implementation (e.g., measured timestamps of algorithm prediction compared to manual, prospectively identified AKI development). Additionally, Investigators will report interventions and clinical outcomes of the prospectively identified patients with AKI, stratified by those predicted early by the model (within 24 hours of admission) versus not.

Interventions

None listed

Sponsors

Adam C Dziorny
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Days to 18 Years
Healthy volunteers
No

Inclusion criteria

* Patients admitted to the Pediatric Intensive Care Unit or Pediatric Cardiac Intensive Care Unit * Age \> 30 days and \< 18 years

Exclusion criteria

* Discharged less than 12 hours after admission * AKI at 12 hours of admission by KDIGO Serum Criteria

Design outcomes

Primary

MeasureTime frameDescription
Acute Kidney Injury (AKI) within the first 72 hours of ICU admissionWithin 72 hours following ICU AdmissionAcute Kidney Injury (AKI) defined by KDIGO stages 1, 2, or 3, based on changes in serum creatinine levels or urine output (UOP), assessed within the first 72 hours of ICU admission. Stage 1 is defined by a 1.5 to 1.9 times baseline serum creatinine or an increase of ≥0.3 mg/dL. Stage 2 is a 2.0 to 2.9 times baseline increase, and Stage 3 is a 3.0 times baseline increase or a serum creatinine ≥4.0 mg/dL.

Secondary

MeasureTime frameDescription
Prediction Accuracy and Timeliness of AKI Risk using a Predictive ModelWithin 12 hours of ICU AdmissionPredictive model results generated prospectively (at 12 hours following admission) will be used to generate a 2x2 confusion matrix with prospectively identified AKI by serum creatinine or urine output changes based on KDIGO criteria. Investigators will calculate sensitivity, PPV, and NNA for the prospective identification of AKI. Investigators will report the time of AKI prediction compared to admission date and the onset date of AKI.
Risk of Mortality in Patients with Acute Kidney Injury (AKI)28 Days following ICU admissionInvestigators will assess for AKI independent risk of mortality at 28 days after adjusting for confounders.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 19, 2026